Editas Medicine, Inc. (EDIT)
Last updated: 2026-10-24 15:16:40. Prices reflect the latest closing data and will resume updating on the next trading day. Stock price data is sourced from Massive.
Summary
Editas Medicine, Inc. (EDIT) operates in the BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) sector and is listed on NASDAQ. The stock is currently priced at $2.39, with a market capitalization of $382.41M and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $1.66 to $3.94. This page covers its latest market performance, valuation, price trends and company information.
Key Market Data
$382.41M | |
$2.44 | |
$99.95 | |
$0.91 | |
$2.49 | |
1.12M | |
2.57M | |
-- | |
$3.94 | |
$1.66 | |
-- | |
-- |
Editas Medicine, Inc. (EDIT) Latest Closing Stock Price
Editas Medicine, Inc. (EDIT) last closed at $2.49 as of 2026-10-23 23:31:00, unchanged from the previous close of $2.49.
During the latest regular trading session, EDIT traded between $0.91 and $99.95, with a volume of 1.12M shares. The closing price was near the lower end and near the lower end of its 52-week range.
Editas Medicine, Inc. (EDIT) 7-Day Stock Price Change
Over the past seven days, Editas Medicine, Inc. (EDIT) moved from $2.44 to $2.39, representing a decline of 2.01% ($0.05).
The stock traded between $2.25 and $2.67 during the period. The latest price is near the middle of the 7-day range, indicating moderate downward.
The average daily volume was 1.60 million shares, down versus the previous seven-day period, indicating lower trading activity.
EDIT 52-Week Price Position
Position in Range: 32.1%
EDIT is currently trading at $2.39, placing it 32.1% of the way from its 52-week low of $1.66 to its 52-week high of $3.94. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
What is Editas Medicine, Inc. (EDIT)?
Editas Medicine Inc is a clinical-stage genome editing company dedicated to developing potentially transformative genomic medicines to treat a broad range of serious diseases. The company focuses on developing a proprietary gene editing platform based on CRISPR technology and continues to expand its capabilities. CRISPR uses a protein-RNA complex composed of an enzyme, including either Cas9 (CRISPR-associated protein 9) or Cas12a (CRISPR from Prevotella and Francisella 1, also known as Cpf1). The company has a single operating segment, which is the business of developing and commercializing gene editing technology.
Editas Medicine, Inc. Information
| Industry | BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) |
| Employees | 87 |
| Exchange | NASDAQ |
| Company Website |
How to Buy Editas Medicine, Inc. (EDIT) Stock on MEXC
Eligible investors can buy real shares of Editas Medicine, Inc. (EDIT) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.
Frequently Asked Questions (FAQ)
1.What is Editas Medicine, Inc. (EDIT) stock price today?
2.Is EDIT stock going up or down today?
3.What is EDIT pre-market price?
4.What is EDIT after-hours price?
5.Is EDIT stock trading now?
6.Where does EDIT sit relative to its 52-week high and low?
7.What sector is Editas Medicine, Inc. in?
8.What is Editas Medicine, Inc.'s market capitalization and where is it listed?
9.How is EDIT valued in terms of P/E ratio and EPS?
10.Does Editas Medicine, Inc. pay a dividend?
Explore More US Stocks
Search Stocks
EDIT Stock Calculator
Estimate the value between EDIT shares and USD.
EDIT Shares to USD
1.00 EDIT shares = 2.391 USD
Calculations are estimates based on the latest available price and are for reference only.


